Prot #DEK-DKK1-P205: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First- Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Ju

Project: Research project

Project Details

StatusActive
Effective start/end date2/10/21 → 2/10/27

Funding

  • Novotech Clinical Research USA, LLC ((OE) Prot #DEK-DKK1-P205 // (OE) Prot #DEK-DKK1-P205)
  • Leap Therapeutics, Inc. ((OE) Prot #DEK-DKK1-P205 // (OE) Prot #DEK-DKK1-P205)